Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis.
Endo Y, Fukui S, Umekita K, Suzuki T, Miyamoto J, Morimoto S, Shimizu T, Koga T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Origuchi T, Okada A, Fujikawa K, Mizokami A, Matsuoka N, Aramaki T, Ueki Y, Eguchi K, Kariya Y, Hashiba Y, Hidaka T, Okayama A, Kawakami A, Nakamura H.
Endo Y, et al. Among authors: matsuoka n.
Mod Rheumatol. 2021 Sep;31(5):972-978. doi: 10.1080/14397595.2020.1847802. Epub 2020 Nov 27.
Mod Rheumatol. 2021.
PMID: 33161771